Contract Manufacturer Supplement
A supplement contract manufacturer (sometimes 'co-packer' or 'CM') is a Part 111-registered facility that manufactures dietary supplements under another firm's brand label. Unlike a pharma CMO, the supplement CM operates under a bilateral compliance regime: both the CM and the own-label distributor (OLD) are personally responsible for Part 111 compliance under §111.12.
Read the full summary
The CM owns physical execution — MMR/BPR, identity testing, finished-product spec, QC disposition — but cannot escape the brand owner's involvement, and a well-built CM operating model treats the bilateral relationship as the unit of compliance.
On this page · 8 sections
- 1What a supplement contract manufacturer is — and is not
- 2The bilateral rule — §111.12 in both directions
- 3Scope allocation — what the CM typically owns vs the brand
- 4The Quality Agreement — every relationship needs one
- 5The support burden — why CM economics are about brand count
- 6Common Warning Letter failure modes for CMs
- 7How brands qualify a CM — and how a CM should prepare
- 8How V5 Ultimate handles contract manufacturing
How does Contract Manufacturer Supplement apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What a supplement contract manufacturer is — and is not
A supplement contract manufacturer is a Part 111-registered facility that manufactures dietary supplements under another firm's brand. Typical scope: ingredient receipt, identity and component testing, weighing, blending, encapsulation / tableting / softgel / liquid-fill, packaging, finished-product testing, holding, and shipping under the brand owner's label. Most US supplement volume is produced by contract manufacturers — not by brand-owned plants. The largest contract manufacturers (NOW Foods, Nutraceutix, Pharmavite, Glanbia, Vitaquest, Capsugel-now-Lonza, etc.) run hundreds of OLD relationships simultaneously.
02The bilateral rule — §111.12 in both directions
21 CFR 111.12(a) puts the obligation on the own-label distributor; the rule does not relieve the contract manufacturer of Part 111 — every Part 111 subpart applies to whoever is performing the operation. The result is that for any given lot, both the CM and the OLD are responsible for the same compliance outcome through different mechanisms: the CM through actual execution, the OLD through oversight, qualification, and accountability. FDA can and does cite both parties for the same observation. A well-run CM understands this structurally and builds the brand-owner relationship into the compliance system — not around it.
03Scope allocation — what the CM typically owns vs the brand
| Activity | Typical CM ownership | Typical OLD ownership | Notes |
|---|---|---|---|
| Formula development | Co-developed or CM-developed | Co-developed or brand-developed | Often the lowest-ambiguity item in the agreement |
| MMR authorship | CM authors, both approve | OLD reviews and approves | MMR is the manufacturer's record but the brand needs access |
| Component identity / qualification | CM executes per §111.75 | OLD audits CM's program | Brand cannot delegate this without retaining oversight |
| Batch record execution (BPR) | CM executes per §111.255–.260 | OLD reviews executed copy | Brand should receive a copy of every executed BPR |
| Finished-product release | CM QC unit signs | OLD QC reviews + accepts | Two-stage release is the defensible pattern |
| Complaint receipt | Either | Either | Bilateral flow-down per quality agreement |
| AE reporting (DSNDCPA) | Notifies brand within 5 business days | Files MedWatch 3500A as 'reporter' | The reporter is the entity on the label (brand) |
| Recall execution | CM supports | OLD coordinates with FDA | Brand is the registered recall coordinator |
| Stability program | CM hosts samples + tests | OLD owns the spec + decisioning | Joint review of stability OOS is the defensible pattern |
| Change control (formula / label / supplier) | Either initiates | Both approve | Either-party initiate, bilateral approve |
04The Quality Agreement — every relationship needs one
FDA's 2016 Quality Agreements guidance is the operational gold standard. The agreement should: identify both parties, define product scope, allocate each Part 111 subpart's tasks (a RACI matrix is the cleanest mechanism), define audit rights and frequency, define batch-record access and retention, define complaint and AE flow-down SLAs, define change-control approvals, define recall coordination, and define termination and record-handover. The agreement is signed by both parties' QC heads and is itself a controlled document under change control.
05The support burden — why CM economics are about brand count
A supplement contract manufacturer's per-brand support load is dominated by document handling: MMRs to maintain (one per SKU per brand), executed BPR copies to send (one per lot per brand), CoAs to issue, complaint and AE notifications to escalate, and quality-agreement updates to negotiate. A CM with 50 brand customers running 4 SKUs each runs 200 active MMRs and ships thousands of executed BPR PDFs per year. Manual handling of that workflow does not scale — and is itself a frequent source of compliance failure (lost MMRs, late AE escalation, BPR sent to wrong brand). Modern CMs therefore invest in MES + brand-portal infrastructure that automates the bilateral document flow, both for compliance and for margin.
06Common Warning Letter failure modes for CMs
- No quality agreement with one or more brand customers — both parties cited.
- MMR changes made without brand sign-off — the manufacturer's QC approved a substitution that the brand never saw.
- Identity test outsourced to an unqualified lab without the brand being informed — the brand assumed in-house testing.
- AE received and held at the CM without escalation to the brand — DSNDCPA 15-business-day clock blown by the time the brand learns of it.
- Stability OOS investigated and closed by the CM without brand involvement — brand learns at the next quarterly review.
- Reserve sample retention failure — neither party physically holds the §111.83 retention sample.
- Cross-contamination between brand A and brand B sharing a line — line clearance and changeover validation gaps.
- Label artwork managed by the brand outside the CM's change-control loop — printed label does not match approved MMR.
07How brands qualify a CM — and how a CM should prepare
A defensible brand-side supplier-qualification programme for a CM includes: (1) document review (cGMP licence, facility registration, NSF/NPA/USP certifications, recent FDA Establishment Inspection Report if available, insurance, financials), (2) on-site or remote audit against a Part 111 checklist (Subparts A–P), (3) sample-lot Quality Agreement red-line, (4) trial-lot manufacture with extended-spec testing, (5) signed Quality Agreement, and (6) annual re-audit cadence. A CM that systematically prepares for this cycle — audit-ready document binders, transparent FDA history, pre-prepared quality-agreement template — wins more brand business and shortens the qualification time from 9 months to 3.
08How V5 Ultimate handles contract manufacturing
- Tenant type 'contract_manufacturer' enables multi-brand routing throughout the system (every WO carries a brand_id alongside the formula).
- Brand portal: per-customer scoped MMR / BPR / CoA / complaint / AE feed.
- Quality Agreement register with version control and per-product scope.
- Bilateral SLA tracker for complaint and AE escalation (CM → brand acknowledgement clock).
- Brand-side e-sig step on BPR release before SHIPPED status is reached.
- Cross-brand changeover and line-clearance workflow with mandatory documentation for shared equipment.
- Label-artwork version control linked to MMR — brand cannot change artwork without re-approving MMR.
Frequently asked questions
Q.Do I need a quality agreement with every brand I manufacture for?+
Yes — FDA expects one. The 2016 guidance is the model, and absence of an agreement is a recurring Warning Letter observation against both parties.
Q.Can I refuse to share MMRs with the brand?+
Operationally you can scope what is shared, but the brand has Part 111 obligations that require access. Most quality agreements grant read access without granting authorship rights — confidentiality is preserved through NDA, not by withholding.
Q.Who is responsible for finished-product release?+
The CM QC unit signs the technical disposition; the brand QC accepts the lot for shipment under their label. Two-stage release is the defensible pattern; single-party release leaves the other party exposed.
Q.What happens to records when a brand leaves me?+
Quality agreement should govern: typically the CM retains records under Part 111 (6-year minimum) but provides a complete copy to the departing brand. Original artwork files return to the brand.
Q.Can I use shared equipment for multiple brands?+
Yes — but cleaning validation and line-clearance documentation must demonstrate no cross-contamination. Each brand's quality agreement should disclose shared-equipment scope.
Q.What's my AE-reporting obligation?+
You must notify the brand within a defined SLA (typically 5 business days for potentially serious AEs); the brand files the MedWatch 3500A as the labelled distributor. Both have a documentation obligation.
Q.How does NSF / NPA / USP certification interact with Part 111?+
Third-party GMP certification is supplier-qualification evidence both for your insurance and for your brand customers' Subpart B audits. It does not replace FDA inspection but materially reduces your qualification friction with sophisticated brand customers.
Primary sources
- 21 CFR 111.12 — Personnel — own-label distributors and contract manufacturers
- FDA Guidance for Industry — Contract Manufacturing Arrangements for Drugs: Quality Agreements (2016)
- 21 CFR 111 Subpart B — Personnel responsibilities
- 21 CFR 111 Subpart H — Production and process controls (master records, batch records)
- NSF International / NPA / USP — GMP audit programmes for dietary-supplement contract manufacturers
- FDA — FSMA facility registration (separate from cGMP)
Further reading
- Own-Label DistributorThe brand-side counterpart of the contract manufacturer relationship.
- CMO / CDMO management (drugs)The drug-industry framework supplement CMs inherit much of their structure from.
- QC unit (111.105)The disposition authority a CM operates daily.
- MMR (111.205/210)Authored by the CM, retained by both parties.
- 21 CFR Part 111The supplement cGMP the entire relationship runs under.
Want to see how Contract Manufacturer Supplement could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.